Nektar Therapeutics (NASDAQ:NKTR) announced on 2 June new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine. Nektar Therapeutics (NASDAQ:NKTR) weekly performance is 6.16%. On last trading day company shares ended up $12.24. Analysts mean target price for the company is $15.71. Nektar Therapeutics (NASDAQ:NKTR) distance from 50-day simple moving average (SMA50) is 7.33%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced on 9 may, net loss was $9,313 for the three months ended March 31, 2014 compared to $11,258 for the same period of 2013. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares advanced 7.23% in last trading session and ended the day on $3.71. PGNX gross Margin is 92.00% and its return on assets is -32.20%.Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is -19.52%.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) on 5 June announced that Greg Madison, the Company’s Chief Operating Officer, will present a corporate overview at the 35th Annual Goldman Sachs Global Healthcare Conference to be held from June 10-12, 2014 at the Terranea Resort in Rancho Palos Verdes, CA. Keryx Biopharmaceuticals (NASDAQ:KERX) shares moved up 6.06% in last trading session and was closed at $14.52, while trading in range of $13.77 – $14.59. Keryx Biopharmaceuticals (NASDAQ:KERX) year to date (YTD) performance is 12.12%.
CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR) ended the last trading day at $4.75. Company weekly volatility is calculated as 6.78% and price to cash ratio as 2.35.CytRx Corporation (NASDAQ:CYTR) showed a positive weekly performance of 17.87%.
Exelixis, Inc. (NASDAQ:EXEL) reported that the President and CEO of the company, Michael M. Morrissey, would be providing an overview of the general corporate activities of the company and its upcoming strategies for growth at the 35th Annual Healthcare Conference to be organized by Goldman Sachs. The conference is scheduled to be held on June 10, 2014 in California. Exelixis, Inc. (NASDAQ:EXEL) weekly performance is 7.67%. On last trading day company shares ended up $3.51. Analysts mean target price for the company is $6.69. Exelixis, Inc. (NASDAQ:EXEL) distance from 50-day simple moving average (SMA50) is 2.46%.
Leave a Reply